Misplaced Pages

Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF). Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF. It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.

References

1. "Vascular endothelial growth factor gene therapy - HSCI". Adis Insight. Springer Nature Switzerland AG.
2. "Gene Therapy for PAD Approved". Drug Discovery and Development. 6 December 2011. Archived from the original on 3 September 2015. Retrieved 5 August 2015.
3. "Neovasculogen listing in Eurolab". Eurolab. Retrieved 4 August 2015.
4. Deev RV, Bozo IY, Mzhavanadze ND, Voronov DA, Gavrilenko AV, Chervyakov YV, et al. (September 2015). "pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia". Journal of Cardiovascular Pharmacology and Therapeutics. 20 (5): 473–82. doi:10.1177/1074248415574336. PMID 25770117. S2CID 13443907.

See also

• Therapeutic angiogenesis

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Approved gene therapies
• Cardiovascular system drug stubs